Not finding it? Sign in to also search OpenAlex live.
-
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Esther Schuler, Eva‐Maria Wagner‐Drouet, Salem Ajib, Gesine Bug, Martina Margrit Crysandt, Sabine Dressler, +19 more
70citations -
Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group2025 Transplantation and Cellular Therapy article Medicine Acute Myeloid Leukemia Research Open access
Christina Rautenberg, Matthias Stelljes, Gesine Bug, Udo Holtick, Edgar Jost, Sara Jennrich, +14 more
3citations -
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Esther Schuler, Eva‐Maria Wagner‐Drouet, Salem Ajib, Gesine Bug, Martina Margrit Crysandt, Sabine Dressler, +19 more
1citations -
Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, +5 more
1citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations -
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
4citations -
S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
M Lübbert, P. W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +26 more
3citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations -
Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML - the SAL/AMLCG Vincent Trial
Leo Ruhnke, Christoph Schliemann, Lars R. Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, +26 more
2citations -
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Julia Stomper, Michal Kiciński, Tobias Ma, Sylvain Chantepie, Richard Noppeney, Mario Luppi, +16 more
0citations -
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
0citations -
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
Michael Lübbert, Pierre W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +32 more
41citations -
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
Olga Grishina, Claudia Schmoor, Caroline Sellner, Björn W. Hackanson, Jan‐Henrik Mikesch, Iordanis Deligiannis, +28 more
0citations -
MPN-756: CPX-351 vs Standard of Care as Bridging to AlloHCT in Patients With Higher-Risk Myelodysplastic Neoplasms or Oligoblastic Acute Myeloid Leukemia: Results of the Randomized Phase 2 PALOMA Study
Uwe Platzbecker, Martina Crysandt, Martin Kaufmann, Andreas Rank, Christoph Röllig, Hartmut Döhner, +30 more
0citations